Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 23, 2019 - Intra-Cellular Therapies’ announced the FDA approval of Caplyta (lumateperone), an atypical antipsychotic indicated for the treatment of schizophrenia in adults.
Return to publications